References

- 1 Gutmann DH, Listernick R, Ferner RE. Screening for symptomatic optic pathway glioma in children with neurofibromatosis type 1 *Eye* 2011; **25**: 818.
- 2 Pilling RF, Lloyd IC, Huson SM. Utility of optic pathway glioma screening in young children with neurofibromatosis type I: questions generated by a clinical audit. *Eye* 2010; 24(10): 1603–1605.
- 3 Krab LC, Aarsen FK, de Goede-Bolder A, Catsman-Berrevoets CE, Arts WF, Moll HA *et al.* Impact of neurofibromatosis type 1 on school performance. *J Child Neurol* 2008; 23(9): 1002–1010.

RF Pilling¹ and RH Taylor²

¹Bradford Royal Infirmary, West Yorkshire, UK ²York District Hospital, Yorkshire, UK E-mail: rfpilling@btopenworld.com

Eye (2011) **25,** 818–819; doi:10.1038/eye.2010.230; published online 28 January 2011

Sir, Brow suspension using 3-0 Prolene

We read with interest your publication of Garrott *et al's*¹ recent case series, highlighting the long-lasting benefit of 2-0 Prolene brow suspension for congenital ptosis. Our experience of ~10 years of performing suture brow suspension in children and adults, for a number of different indications, echoes these findings. In addition, we found that repeat brow suspension, when necessary, was a more straightforward undertaking using this technique. This technique avoids the sequelae of autologous fascia lata harvesting² and the soft tissue complications associated with the use of mersilene mesh.³

A retrospective case note review highlighted 41 eyes having undergone brow suspension surgery using 3-0 Prolene over a 9-year period (2001–2009) at our institute. All cases with a levator function of <5 mm were included in the analysis, irrespective of cause of ptosis and age, to provide a realistic clinical picture. Mean age at operation was 23 years (range 1–74 years). Recorded palpebral aperture improved significantly following the surgery (P<0.0005; mean 4 mm pre-operation, 7 mm post-operation). The majority were free from complications, although seven (17%) experienced a recurrence of their ptosis requiring a further operation and five (12%) experienced discomfort or a lump at the site of the suture knot. The Kaplan–Meier plot shows the cumulative survival for the group (Figure 1).

Unfortunately, no randomized controlled trials have been undertaken to determine the optimal material for brow suspension surgery. We commend Garrott *et al* for publishing their long-term outcomes and agree that fascia lata brow suspension is not a prerequisite for successful, long-lasting brow suspension surgery in children. Indeed fascia lata use is not without its complications, at both the harvesting site² and through proposed contracture of the fascia lata itself leading to variability in the cosmetic results.⁴ In addition, we suggest a Prolene sutured brow suspension can be used




Figure 1 Kaplan–Meier plot demonstrating cumulative survival for brow suspensions using 3-0 Prolene.

in a broader group of patients, to provide adults with ptosis and poor levator function, a cosmetically and functionally satisfactory result in the long-term. It is worth noting that we have performed this procedure under local anaesthesia in a small number of adults. It is an easily reversible and repeatable procedure.

Conflict of interest

The authors declare no conflict of interest.

References

- Garrott H, Aristodemou P, Sinclair N, Lane C, Harrad R. Long-term efficacy of 2-0 Prolene brow suspensions for congenital ptosis. *Eye* 2010; 24(1): 175–177.
- 2 Bleyen I, Hardy I, Codère F. Muscle prolapse after harvesting autogenous fascia lata used for frontalis suspension in children. *Ophthal Plast Reconstr Surg* 2009; 25(5): 359–360.
- 3 Mehta P, Patel P, Olver JM. Functional results and complications of mersilene mesh use for frontalis suspension ptosis surgery. *Br J Ophthalmol* 2004; **88**(3): 361–364.
- 4 Yoon JS, Lee SY. Long-term functional and cosmetic outcomes after frontalis suspension using autogenous fascia lata for pediatric congenital ptosis. *Ophthalmology* 2009; 116(7): 1405–1414.

AA Mokashi, RE Stead and LC Abercrombie

Department of Ophthalmology, Nottingham University NHS Trust, Queens Medical Centre, Nottingham, UK E-mail: aamokashi@gmail.com

Eye (2011) **25,** 819; doi:10.1038/eye.2011.8; published online 11 February 2011